Pharma Stocks Outlook
Seen in range next wk; muted Q2 results to weigh
This story was originally published at 19:37 IST on 14 November 2025
Register to read our real-time news.Informist, Friday, Nov. 14, 2025
MUMBAI – Shares of pharmaceutical companies are seen in a range due to a lack of major triggers. Additionally, companies reported muted growth in the September quarter. Some big Indian companies with significant exposure to the US market may see a marginal impact on their speciality product portfolios in the coming quarters due to the Trump administration's recent deal with Eli Lilly and Novo Nordisk, according to analysts.
Last week, US President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments. The agreements will lower the prices of Glucagon-like Peptide-1 drugs on Medicare and Medicaid schemes. The agreements will offer patients discounted treatments directly on TrumpRx.gov, a website the Trump administration will launch in January.
Analysts suggest that the new Most Favoured Nations pricing for these drugs by the US government may put near-term pricing pressure on Indian companies with a larger speciality product portfolio.
"The recent record-breaking US government shutdown may have an adverse impact on Indian drug makers as the abbreviated new drug application approvals by the US Food and Drug Administration fell in the month of October," said Mehul Sheth, research analyst at HDFC Securities, talking about factors which could dent the earnings of the drug-makers in the coming quarters.
Sheth said that the phasing out of gRevlimid sales will impact Indian companies and is expected to reflect in the December quarter results.
The Nifty Pharma index ended the week nearly 3% higher at 22821.05 points. The index is expected to find support around 22600 points and encounter resistance around 23000 points, said Rupak De, technical research analyst at LKP Securities. IPCA Laboratories was the biggest gainer during the week, rising over 12%, followed by Aurobindo Pharma, which ended nearly 9% higher. Piramal Pharma and Divi's Laboratories fell by over 2% each.
TOP HEADLINES
* Natco Pharma Jul-Sep consol PAT down 23.5% on year as sales fall 0.6%
* Aurobindo Pharma arm's unit tagged 'voluntary action indicated' by US FDA
* Biocon clarifies co still in process of evaluating Biocon Biologics' merger
* Lupin launches Risperidone for extended-release injectable suspension in US
* US FDA issues 2 observations post inspection at Zydus Life's oncology unit
* Concord Biotech Jul-Sept consol PAT falls 34% YoY as sales drop 20%
* Analyst Concall: Alkem Lab to continue double-digit growth in India Oct-Mar
* Akums Drugs Jul-Sept PAT falls 53.4% YoY as sales fall 5.8%
* Zydus Lifesciences gets US FDA's final nod for diroximel fumarate capsules
* Earnings Review: Alkem Lab Q2 consol PAT up 11% on year, beats view
* Zydus Life's French step-down arm gets EU nod for orthopaedic robotic system
* Ipca Labs Jul-Sept net profit rises nearly 25% YoY to INR 3.05 billion
* Granules India Jul-Sept consol PAT rises 34.3% YoY to INR 1.3 billion
* Alembic Pharma gets US FDA nod for Dexlansoprazole delayed-release capsules
* Lupin's Aurangabad facility gets US FDA establishment inspection report
* Entero Healthcare Jul-Sept consol PAT rises 33.8% YoY to INR 316.01 million
* Cohance Lifesciences Jul-Sept consol PAT falls 46.5% YoY as sales fall 8%
* Delhi HC refuses to allow Johnson & Johnson arm to sell remaining ORSL drink
* Sun Pharma presents early data on GLP-1 drug Utreglutide in US
* Pfizer Jul-Sept net profit rises over 19% YoY to INR 1.89 billion
* Eris Life Jul-Sept consol net profit rises 31% YoY to INR 1.2 billion
* Analyst Concall: PI Industries retains FY26 EBITDA margin guidance of 26-27%
* Lupin arm commissions dedicated oncology block at Vizag facility
* Analyst Concall: Biocon expects interest cost savings of INR 3 bln in FY27
* Sun Pharma's partner Philogen releases updates of Fibromun clinical study
* Earnings Review: Biocon Q2 revenue beats view, PAT slightly misses estimate
* OneSource Specialty posts INR 104.85-mln consol PAT Jul-Sept vs loss yr ago
* JB Chemicals Jul-Sept PAT rises 15.8% on year to INR 2 bln
* Emcure Pharma Jul-Sept consol PAT rises 25% YoY to INR 2.43 billion
* Dr. Reddy's says no loss to co due to incident of cyber fraud
* Zydus Life gets approval from China drug regulator for Venlafaxine capsules
* Granules India arm gets US FDA approval for pdt for Hyderabad facility
* On Dabur plea, HC bars Patanjali Ayurved from airing advt on chyawanprash
* Glenmark Pharma arm gets China body's nod for compound nasal spray Ryaltris
* Emcure Pharma partners with Novo Nordisk to launch Poviztra in India
* Biocon gets 2 observations from US FDA for its Vizag unit after inspection
* US FDA ends clinical inspection at Lupin's Pune unit with no observations
* NCLT OKs merger of Max Healthcare arms Jaypee Healthcare, Crosslay Remedies
* Analyst Concall: Torrent Pharma aims to complete JB Chemical's buyout by Jan
* Earnings Review:Torrent Pharma sees 6-qtr high YoY PAT growth at INR 5.9 bln
* Earnings Review: Torrent Pharma sees 6-qtr high YoY PAT growth at INR 5.9 bln
* Analyst Concall: Lupin revises FY26 EBITDA margin guidance upwards to 25-26%
* AstraZeneca Pharma Jul-Sept net profit rises 41% YoY to INR 542.2 million
* Analyst Concall: Divi's Lab to exceed FY26 capex aim on capacity expansion
* Neuland Labs Jul-Sept consol PAT up nearly 3-fold YoY at INR 968.5 million
* Alembic Pharma gets US FDA's final approval for sumatriptan injection
Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:
| Company | Price | Week-on-Week Change in % | Resistance | Support |
| Abbott India | 29340.00 | 1.90 | 30233.30 | 28153.30 |
| Alkem Laboratories | 5722.50 | 1.00 | 5913.80 | 5511.80 |
| Aurobindo Pharma | 1222.50 | 8.80 | 1248.10 | 1190.10 |
| Biocon | 411.15 | 8.10 | 425.00 | 401.10 |
| Cipla | 1532.10 | 1.80 | 1541.90 | 1517.10 |
| Divi's Laboratories | 6511.50 | (-)2.20 | 6692.50 | 6390.50 |
| Dr Reddy's Laboratories | 1246.00 | 3.40 | 1259.50 | 1225.10 |
| Gland Pharma | 1830.00 | (-)1.80 | 1885.20 | 1784.60 |
| GlaxoSmithKline Pharmaceuticals | 2479.40 | (-)4.20 | 2532.80 | 2444.20 |
| Glenmark Pharmaceuticals | 1895.60 | 4.60 | 1971.10 | 1817.30 |
| Granules India | 548.20 | (-)1.20 | 572.00 | 530.70 |
| Ipca Laboratories | 1479.60 | 12.20 | 1687.20 | 1201.20 |
| Laurus Labs | 999.00 | 1.70 | 1023.60 | 980.70 |
| Lupin | 2055.30 | 4.20 | 2086.80 | 2020.00 |
| Natco Pharma | 812.65 | 1.30 | 839.60 | 793.60 |
| Pfizer | 5074.00 | (-)0.00 | 5118.00 | 5006.00 |
| Sanofi India | 4581.10 | (-)1.20 | 4635.00 | 4533.00 |
| Sun Pharmaceutical Industries | 1757.10 | 3.90 | 1776.00 | 1725.20 |
| Torrent Pharmaceuticals | 3831.80 | 7.00 | 3905.50 | 3766.10 |
| Zydus Lifesciences | 944.45 | 0.00 | 959.10 | 932.20 |
| Nifty Pharma | 22821.05 | 2.90 | 22993.90 | 22562.60 |
| Nifty 50 | 25910.05 | 1.60 | 26063.10 | 25664.30 |
| S&P BSE Sensex | 84562.78 | 1.60 | 85098.50 | 83761.40 |
End
Reported by P.Madhu Kumar
Edited by Saji George Titus
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
